Avalon GloboCare to Present at the 32nd Annual ROTH Conference on March 16, 2020
February 24 2020 - 8:30AM
Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global
developer of cell-based technologies and therapeutics, announced
today that it will present at the 32nd Annual ROTH Conference being
held on March 15-17, 2020 at The Ritz-Carlton, Laguna Niguel in
Dana Point, CA.
David Jin, M.D., Ph.D., President and Chief Executive Officer of
Avalon GloboCare is scheduled to present on Monday, March 16, at
3:30 p.m. Pacific Time. He will be joined by the Company's Chief
Financial Officer, Luisa Ingargiola, for the presentation and
one-on-one meetings with institutional analysts and investors.
A live webcast and archive of the presentation will be available
on Avalon’s investor relations page at:
https://ir.avalon-globocare.com/.
About The 32nd Annual ROTH Conference
The 32nd Annual ROTH Conference is scheduled for March 15-17,
2020 at The Ritz Carlton, Laguna Niguel in Orange County, CA.
Following the success of the previous year's events, the ROTH
Conference, with close to 550 participating companies and over
5,100 attendees, will feature presentations from public and private
companies in a variety of sectors.
For more information, please contact your ROTH
Representative.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage,
leading CellTech bio-developer dedicated to advancing and
empowering innovative, transformative exosome technologies and
cellular therapeutics. Avalon also provides strategic advisory and
outsourcing services to facilitate and enhance its clients' growth,
development, as well as competitiveness in healthcare and CellTech
industry markets. Through its subsidiary structure with
unique integration of verticals from innovative R&D to
automated bioproduction and accelerated clinical development,
Avalon is establishing a leading role in the fields of in vitro
diagnostics (''liquid biopsy''), immune effector cell therapy
(including CAR-T/CAR-NK), and regenerative therapeutics. For more
information about Avalon GloboCare, please visit
www.avalon-globocare.com.
Forward-Looking Statements
Certain statements contained in this press release may
constitute "forward-looking statements." Forward-looking statements
provide current expectations of future events based on certain
assumptions and include any statement that does not directly relate
to any historical or current fact. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors as disclosed in our
filings with the Securities and Exchange Commission located at
their website (http://www.sec.gov). In addition to these factors,
actual future performance, outcomes, and results may differ
materially because of more general factors including (without
limitation) general industry and market conditions and growth
rates, economic conditions, and governmental and public policy
changes. The forward-looking statements included in this press
release represent the Company's views as of the date of this press
release and these views could change. However, while the Company
may elect to update these forward-looking statements at some point
in the future, the Company specifically disclaims any obligation to
do so. These forward-looking statements should not be relied upon
as representing the Company's views as of any date subsequent to
the date of the press release.
Contact Information: Avalon GloboCare Corp.4400 Route 9, Suite
3100Freehold, NJ 07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo Communications, LLCTel: (212)
671-1020 Ext. 304avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Apr 2023 to Apr 2024